Stada And Alvotech Launch Higher-Strength Adalimumab In Europe

Hukyndra Biosimilar To Humira Introduced In France, Germany, Finland And Sweden

Stada and Alvotech have announced the launch of the Hukyndra higher-strength adalimumab biosimilar rival to Humira in selected European countries, with a wider roll-out to follow in the coming months.

Europe from space
Stada and Alvotech have begun their launch across Europe • Source: Shutterstock

Stada has now launched the AVT02 higher-strength 100mg/ml adalimumab biosimilar developed by Alvotech in Europe under the name Hukyndra, with an initial roll-out focusing on “selected European countries, including France, Germany, Finland, and Sweden,” ahead of launches in further European countries that Stada says are scheduled “over the coming months.”

The company said it would support Hukyndra launches in individual national markets “through tailored educational materials and well as dedicated...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.